PReS-FINAL-2076: Single centre experience of biologics in clinical practice of systemic juvenile idiopatic arthritis

Methods Our retrospective study included 59 Pts (20 boys, 39 girls), who used B. All Pts had diagnosis of sJIA, established according to the ILAR classification criteria. The clinical characteristic at the time of 1 prescription: mean age of 6.25, range 2.0-17.75 yrs; mean disease duration of 4.5, range 0.3-15.9 yrs; 61% of Pts had active systemic features, 98.3% arthritis. The previous therapy included NSAIDs (95%), steroids (76%), DMARDs (methotrexate (MTX) alone 18.6%, 2 DMARDs 68%, 3 DMARDs consecutive 12%). As the 1 B used: infliximab (INF) 32%, tocilizumab (TCZ) 39%, etanercept (ETA) 10%, adalimumab (ADA) 9%, abatacept (ABA) 5%, rituximab (RTM) 5%. 39 Pts received only 1 B: by 12.8% INF or ADA, 53.8%TCZ, 15.4%ETA, by 2.6% RTM or ABA. 22 Pts received 2 B successively, the 2 B used: 50%TCZ, 13%ETA, 14%ADA, 14%ABA, 9% RTM. 9 Pts received 3 B, the 3d B used: 45%TCZ, 22% ABA, 22% canacinumab (CAN), 11%ADA. 2 Pts received successively 4 B (INF-ADA-TCZ-ABA, INF-TCZ-ABAETA). The reasons for substitution therapy were serious adverse effects (SAE), subsequent loss of effect. We did not use anakinra because it is not available in Russia.